BRPHF yields 9.20% · PFE yields 6.20%● Live data
📍 PFE pulled ahead of the other in Year 10
Combined, BRPHF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of BRPHF + PFE for your $10,000?
Galaxy Digital Holdings Ltd., an asset management firm, operates in the digital asset, cryptocurrency, and blockchain technology industry. It operates through five segments: Trading, Principal Investments, Asset Management, Investment Banking, and Mining. The company provides spot, derivate, and financing liquidity to institutional clients, counterparties, and venues that transact in cryptocurrencies and other digital assets; and offers access to traded cryptocurrencies to clients and counterparties across a suite of service offerings, including over-the-counter (OTC) spot liquidity provision, on- exchange liquidity provision, OTC options and trading, and bespoke lending and structured products, as well as engages in the proprietary quantitative, arbitrage, and macro trading strategies. It also manages third party capital across traditional and alternative asset classes. In addition, the company offers financial advisory services, such as general corporate, strategic, mergers and acquisitions, divestitures, and restructuring advisory services, as well as equity, debt, and project finance capital markets services to public and private clients. Further, it has a strategic focus to provide financial tools to North American miners, as well as has partnership with third-party data center providers and hosts its proprietary bitcoin mining equipment for helping to secure the Bitcoin network. Additionally, the company manages various portfolio of private investments across the digital assets industry, such as traditionally structured companies, as well as in those building digital asset networks powered and capitalized by tokens. Galaxy Digital Holdings Ltd. is headquartered in New York, New York.
Full BRPHF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.